TroyGould Represents Lixte Biotechnology Holdings, Inc. in Public Offering of Common Stock and Warrants
TroyGould advised Lixte Biotechnology Holdings, Inc. in its public offering of 1,200,000 units, each consisting of one share of common stock and one warrant to purchase common stock at an offering price of $4.75 per unit for total gross proceeds of $5.7 million. Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with cancer and other serious common diseases to design novel compounds to attack those targets. The offering closed on December 1, 2020. In connection with the offering, Lixte granted the underwriters a 45-day option to purchase up to 180,000 additional shares of the Company’s common stock and/or up to 180,000 additional warrants to purchase shares of the Company’s common stock, or any combination thereof, to cover overallotments, if any. The shares and warrants were immediately separable, were issued separately, and began trading on The Nasdaq Capital Market on November 25, 2020, under the symbols “LIXT” and “LIXTW”, respectively. WestPark Capital, Inc. and WallachBeth Capital, LLC acted as the joint book-running managers for the offering. The TroyGould team was led by David Ficksman. For more information, see this press release.
Celebrating 50 years of success as one of Southern California’s leading business law firms, TroyGould is recognized in the U.S. and abroad for its success in helping both U.S. and non-U.S entities and individuals achieve their business goals. The firm’s transactional and litigation clients range from emerging companies to middle-market and Fortune 500 companies across a diverse set of industries including life sciences, technology, entertainment/media, manufacturing, food and beverage, real estate, consumer products and health care. For more information, visit TroyGould.com.